# The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk

> **NCT05943821** · PHASE3 · RECRUITING · sponsor: **Poznan University of Medical Sciences** · enrollment: 1116 (estimated)

## Conditions studied

- Cardiovascular Diseases
- Uric Acid

## Interventions

- **DRUG:** Allopurinol 200 mg
- **DRUG:** Optional intervention

## Key facts

- **NCT ID:** NCT05943821
- **Lead sponsor:** Poznan University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 1116 (ESTIMATED)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05943821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05943821, "The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05943821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*